Nonivamide

Nonivamide

SCHEMBL29425552

CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2D6 P10635 2/20 1.00
HPGD P15428 2/20 1.00
ALDH1A1 P00352 1/20 1.00
CYP2C9 P11712 1/20 1.00
ALOX15 P16050 1/20 1.00
CYP2C19 P33261 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
TRPV1 Q8NER1 9/20 0.93
MEN1 O00255 1/20 0.87
TP53 P04637 1/20 0.87
MAPT P10636 1/20 0.87
MTOR P42345 1/20 0.87
KMT2A Q03164 1/20 0.87
EPHX2 P34913 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669968 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL29368417 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL5088067 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL1155582 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
Nonivamide SCHEMBL81939 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL8373082 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL1155739 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL679954 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL2400979 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1
SCHEMBL5889449 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4210687-B1 TRPV1 AGONISTS IN THE PREVENTION OF DIABETIC ULCERS IMPERIAL COLLEGE INNOVATIONS LTD (GB) 2026-05-27 EP claimed
EP-3911172-B1 COMBINATION OF SATIETY COMPONENTS WITH ARGININE SYMRISE AG (DE) 2026-04-15 EP claimed
EP-3595697-B1 CLEAVABLE ESTERS FOR NANOCARRIER-BASED CANCER THERAPY CHILDRENS HOSPITAL PHILADELPHIA (US) 2025-02-12 EP claimed
EP-4486857-A1 FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT International Flavors & Fragrances Inc. (US) 2025-01-08 EP claimed
EP-3969163-B1 BIODEGRADABLE POLYUREA/POLYURETHANE MICROCAPSULES SYMRISE AG (DE) 2024-12-11 EP claimed
EP-4452941-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-10-30 EP claimed
WO-2023168069-A1 FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2023-09-07 WO claimed
EP-3142779-B1 FOAM PRODUCTION EQUIPMENT AND METHOD POULNAIS ERIC (FR) 2023-04-26 EP claimed
EP-4033887-A1 METHOD FOR CONTROLLED ELICITATION OF PEPPER PLANTS UNDER CULTIVATION TO INCREASE THEIR SYNTHESIS OF SECONDARY METABOLITES OF INDUSTRIAL INTEREST ID4Feed (FR) 2022-08-03 EP claimed
EP-3131531-B1 TOPICAL COMPOSITIONS FOR PAIN RELIEF, MANUFACTURE AND USE PROPELLA THERAPEUTICS INC (US) 2022-04-06 EP claimed
EP-3388057-B1 A PAIN RELIEF COMPOSITION, COMPRISING A TRPV1 SELECTIVE AGONIST, AND MANUFACTURE AND USES THEREOF PROPELLA THERAPEUTICS INC (US) 2022-03-09 EP claimed
EP-3744322-B1 PATCH HISAMITSU PHARMACEUTICAL CO (JP) 2022-03-09 EP claimed
EP-4223352-B1 DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS UROTRONIC INC (US) 2026-05-27 EP disclosed
WO-2026087745-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-30 WO disclosed
EP-4732825-A1 AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE BRAIN Biotech AG (DE) 2026-04-29 EP disclosed
US-12605342-B2 Polymer-encapsulated drug particles TONIC MEDICAL, INC. (US) 2026-04-21 US disclosed
EP-3969163-A1 BIODEGRADABLE POLYUREA/POLYURETHANE MICROCAPSULES Symrise AG (DE) 2022-03-23 EP disclosed
EP-3969164-A1 METHOD FOR PRODUCING MICROCAPSULES Symrise AG (DE) 2022-03-23 EP disclosed
EP-3969162-A1 POLYUREA/POLYURETHANE MICROCAPSULES Symrise AG (DE) 2022-03-23 EP disclosed
EP-3969165-A1 BIODEGRADABLE POLYUREA/POLYURETHANE MICROCAPSULES Symrise AG (DE) 2022-03-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605342-B2 Polymer-encapsulated drug particles MUC1, SLC10A2, EGFR CYP1A2 1652/4885CYP3A4 1392/4885CYP2D6 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.